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Work from this laboratory has identified a  unique lymphokine that activates 
macrophage receptors for the third complement component (C3)  so that they 
promote phagocytosis of C3-coated particles (1-6).  The iymphokine exerts its 
effect via a novel mechanism. Macrophage C3 receptors are normally unable to 
move within the cell's plasma membrane and, even though they promote very 
efficient particle binding, are unable to promote phagocytosis (7). The lympho- 
kine acts by freeing the immobilized receptors, enabling them to move within 
the cell's plasma membrane (5). When ligated by particle-bound C3, the mobile 
receptors are free to move laterally, perhaps to aggregate among themselves or, 
more likely, to become associated with other plasma membrane or subplasmalem- 
mal molecules that act as second messengers, thereby generating and propagating 
a phagocytic signal, which activates the cell's intracellular phagocytic machinery. 
To better understand the mechanism by which the lymphokine acts, it would 
be ideal to identify the macrophage molecule(s) with which the mediator interacts. 
It seemed likely that the lymphokine interacts first at the macrophage surface, 
perhaps via a  specific lymphokine receptor.  In the present studies, we sought 
evidence for such a receptor. The results strongly suggest that the lymphokine 
binds to a fucose-containing glycoprotein on the macrophage surface. 
Materials and Methods 
Reagents and Media.  Dispase  was obtained from Boehringer  Mannheim Biochemicals, 
Indianapolis, IN; L-fucose, n-fucose, mannose, ~galactose, N-acetyl-~glucosamine,  glu- 
cose, arabinose,  2-deoxy-D-glucose, D-xylose, gorse lectin, wheat germ agglutinin, poke- 
weed mitogen, phytohemagglutinin  (PHA)) concanavalin A (Con A), trypsin (lot T8253, 
twice recrystallized), and fucosidase were obtained from Sigma Chemical Co., St. Louis, 
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t Abbreviations used in this paper:  C3, third component  of complement; Con A, concanavalin  A; 
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PHA, phytohemagglutinin;  PMA, phorbol myristate  acetate. 
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MO; glutaraldehyde,  50%  aqueous solution, was purchased from Fisher Scientific Co., 
Atlanta,  GA; ovomucoid trypsin inhibitor was obtained from Worthington  Biochemical 
Corp., Freehold, NJ; medium 199 was purchased from Microbiological Associates, Walk- 
ersville,  MD;  and  fetal  bovine serum  (FBS)  and penicillin-streptomycin were obtained 
from Gibco Laboratories, Grand Island, NY. FBS was heat inactivated (56°C for 30 min) 
before use. 
Sheep erythrocytes (E) in Alsever's solution, obtained from Scott Laboratories, Fiske- 
ville, RI, were washed three times in phosphate-buffered saline (PBS) and resuspended in 
medium. A 4.05% aqueous solution of Brewer thioglycollate medium (Difco Laboratories, 
Detroit, MI) was prepared according to the manufacturer's directions. 
Immunologically Coated Sheep E.  Rabbit anti-sheep E IgM and rabbit anti-sheep E IgG 
were obtained from Cordis  Laboratories, Miami,  FL.  Sheep E  coated with anti-E IgG 
(EIgG) or with  anti-E  IgM and  the  first four complement components (EIgMC) were 
prepared as previously described (7). 
Animals.  Peritoneal macrophages, thymocytes, and serum used to prepare immobilized 
immune complexes were obtained from 20-30 g female, CD-1 Swiss mice (Charles River 
Breeding Laboratories, Inc., Wilmington, MA). C5-deficient mouse serum was obtained 
from female C5-deficient AKR mice (The Jackson Laboratory, Bar Harbor, ME).  Both 
AKR and CD-1 mouse serum were adsorbed twice at 4°C for 15 rain with 20% sheep E 
before being frozen in small aliquots at -70 °C. Serum was thawed on ice just before use 
as a complement source. 
Macrophages.  Resident  mouse peritoneal macrophages were obtained by peritoneal 
lavage  and  cultured  on  glass  coverslips  in  petri  dishes,  as  previously  described  (8). 
Macrophages elicited with thioglycollate medium were harvested 4 d after intraperitoneal 
injection of 1 ml/mouse of thioglycollate medium and cultured  in the same manner as 
resident peritoneal macrophages. 
Preparation of Coverslips.  Coverslips used for phagocytosis assays were sterilized and 
used  without  further  treatment.  Coverslips used  for C3  receptor mobility assays were 
coated with complement-containing immune complexes as previously described (5, 9). 
Preparation of Lymphokine.  Culture supernatants containing the lymphokine that ena- 
bles resident mouse peritoneal macrophages to ingest C3-coated particles were prepared 
and used as previously described (1, 2). 
Assessment of Macrophage Fc and  C3 Receptor Function.  After a  48-h  incubation  in 
medium-10%  FBS,  macrophage monolayers were washed,  some were subjected to the 
treatments  indicated,  washed  again,  some  were  overlaid  with  lymphokine-containing 
supernatant,  0.2  ml  of 0.5%  EIgG or  EIgMC  was  added  to  the  dishes,  and  cultures 
incubated for 30 min at 37°C. The cultures were then washed twice with PBS and fixed 
with  2.5%  glutaraldehyde in  0.1  M cacodylate buffer, and E attachment and ingestion 
were scored by phase contrast microscopy. 
Assessment of Macrophage C3 Receptor Mobility.  Freshly  harvested  mouse  peritoneal 
macrophages  were  plated  on  coverslips  coated  with  complement-containing  immune 
complexes. After a 1-h incubation to allow macrophages to adhere, coverslips were washed, 
some were subjected to the treatments indicated, washed again, and some were overlaid 
with  lymphokine-containing supernatant.  After a  15-min  incubation  at  37°C,  cultures 
were washed and the macrophages" ability to bind EIgMC assessed as previously described 
(5). 
Presentation of Results.  Each result reported is the average of at least three separate 
determinations, each performed in duplicate. Attachment Index and  Phagocytic Index 
are the number of E attached or ingested by 100  macrophages, and were obtained by 
multiplying the  percent  of macrophages that  had  attached  or  ingested  any E  by the 
average number of E attached or ingested per macrophage. Each result is presented as 
the mean +  SEM. 
Results 
Effect of  Protease Treatment on the Macrophage's  Ability to Respond to the Lympho- 
kine.  Cell  surface  receptors  for  a  number  of ligands  are  proteins  (10).  We 1208  MACROPHAGE RECEPTOR FOR A LYMPHOKINE 
initially sought evidence for a protein receptor for the lymphokine by attempting 
to destroy it with proteases. Experiments using varying concentrations of trypsin 
were unsuccessful because, even in fairly low concentrations, trypsin treatment 
destroyed macrophages' C3 receptors (data not shown), thereby abolishing the 
assays for lymphokine activity, C3  receptor-mediated particle attachment, and 
phagocytosis. 
Dispase, a neutral protease from Bacillus polymyxa (11), proved ideal for these 
studies because it  had no effect on  macrophages'  C3  receptors.  Macrophages 
were treated with varying concentrations of Dispase at 37°C for 30 min, after 
which they were washed, overlaid with lymphokine, and assessed for their ability 
to phagocytize EIgMC. In a dose-dependent fashion, Dispase treatment abolished 
the  macrophage's ability  to  respond  to  the iymphokine and  phagocytize C3- 
coated E (Fig.  1).  Dispase did not exert its effect by killing or non-specifically 
injuring macrophages because Dispase-treated macrophages could phagocytize 
EIgG  normally (data  not shown) and  could recover completely the ability to 
respond to the lymphokine and phagocytize via their C3 receptors within several 
hours of removal of the enzyme (Fig. 2). 
Because  the  assay  for  lymphokine  activity  was  phagocytosis  mediated  by 
macrophages' C3 receptors, failure of macrophages to ingest EIgMC could have 
been due either to Dispase's affecting the C3 receptors per se or to its interfering 
with  the  lymphokine's interaction  with  macrophages. To distinguish  between 
these possibilities,  we performed the following control experiments.  First,  we 
assessed the ability of Dispase-treated macrophages to bind EIgMC; it was normal 
and no different from that of nontreated macrophages (data not shown). Second, 
we assessed the ability of thioglycollate-elicited macrophages, cells that sponta- 
neously  phagocytize  via  their  C3  receptors,  to  ingest  EIgMC  after  Dispase 
treatment. Dispase had no effect on these cells' ability to phagocytize EIgMC 
(Fig.  1). Thus, it is very unlikely that Dispase treatment affected macrophage's 
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FIGURE 1.  Effect  of Dispase  treatment on macrophages'  ability  to respond  to the lymphokine 
and to phagocytize  EIgMC. Resident  (----4t--)  or thioglycollate-elicited  (+)  mouse  perito- 
neal macrophages  were treated with Dispase for 30 min at 37°C. The cells were washed, 
resident macrophages  were overlaid  with lymphokine,  and both macrophage  populations were 
assayed for their ability to ingest EIgMC. GRIFFIN AND MULLINAX  1209 
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FIGURE  2.  Recovery of macrophages from the effects of Dispase treatment. Resident mouse 
peritoneal macrophages that had been treated with  I  mg/ml of Dispase for 30 rain at 37°C 
were washed and overlaid with medium. At the times indicated these cells were assayed for 
their ability to ingest EIgMC (---0--). The Phagocytic Index of macrophages that were not 
subjected to Dispase treatment is indicated (II). 
C3 receptors.  Rather,  its effect was on the interaction of the lymphokine with 
the macrophage, probably interference with the binding of the lymphokine to a 
cell surface protein. 
We have previously found that there is a precise correlation between mobility 
of macrophage C3 receptors and the ability of the receptors to promote phago- 
cytosis  (5,  6).  Moreover,  we  found  that  manipulations  of macrophages  that 
abrogated one response to the lymphokine, C3 receptor-mediated phagocytosis, 
also abrogated  the other response, C3  receptor mobility (5,  6).  To determine 
whether or not Dispase treatment abrogated both lymphokine effects, we assessed 
the C3 receptor mobility of Dispase-pretreated, lymphokine-treated macrophages 
by  determining the ability  of macrophages plated  on  complement-containing 
immune complexes and treated first with Dispase and then with lymphokine to 
bind EIgMC. In this assay, C3 receptors that are mobile become trapped on the 
immobilized immune complexes when they diffuse randomly from the nonad- 
herent to the adherent macrophage surface; macrophages with mobile receptors 
therefore  lose  the  ability  to bind  EIgMC.  In  contrast,  C3  receptors  that  are 
immobile are unable to diffuse within the macrophage plasma membrane and 
remain in place even when macrophages are plated on immune complexes; these 
macrophages therefore retain the ability to bind EIgMC.  Dispase treatment of 
macrophages abrogated lymphokine-induced C3 receptor mobility because Dis- 
pase-pretreated,  lymphokine-treated macrophages retained  the ability to bind 
EIgMC (Table I, line 4). 
Effect of  Sugars on the Interaction of the Lymphokine with Macrophages.  Receptors 
for a  number of ligands are glycoproteins (12-15),  and specific sugar residues 
on receptor molecules have been found to be essential in the binding of certain 
ligands (16-20).  We sought a  role for specific sugars in mediating lymphokine 
binding by trying to competitively inhibit its binding with a  number of sugars. 
Experimental sugars were added at either 0.1  M or other indicated concentra- 
tions to lymphokine-containing supernatants. After a 15-min incubation at 37 o  C, 
these  supernatants,  containing  both  lymphokine  and  sugar,  were  added  to 
macrophages and the macrophages' ability to ingest EIgMC assessed. 1210  MACROPHAGE  RECEPTOR  FOR  A  LYMPHOKINE 
TABLE  I 
Effect of Dispase Treatment of Macrophages on Lymphokine-induced 
C3 Receptor Mobility 
Treatment of macrophages with: 
Dispase  Lymphokine 
Attachment Index of EIgMC 
-  -  1,030 +-  140 
+  -  998 +  184 
-  +  41+_3 
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FIGURE 3.  Effect  of L-fucose on  the ability of lymphokine to activate macrophage C3 
receptors for phagocytosis.  L-Fucose  was added in the concentrations  indicated  to lymphokine- 
containing supernatants. Resident mouse  peritoneal macrophages  (+)  were overlaid with 
the supernatants and assayed for their ability to ingest EIgMC. The ability  of thioglycollate- 
elicited macrophages  to ingest EIgMC in the presence of L-fucose  was also assessed (11). 
Inclusion of L-fucose in the incubation mixture abolished, in a dose-dependent 
manner, the ability of macrophages to respond to the lymphokine and phagocy- 
tize EIgMC (Fig. 3). L-Fucose did not exert its effect simply by harming the cells 
because L-fucose-treated macrophages ingested EIgG normally (data not shown). 
Moreover, L-fucose treatment had no direct effect on macrophages' C3 receptors 
because L-fucose-treated, thioglycollate-elicited  macrophages retained the ability 
to phagocytize EIgMC (Fig. 3).  Finally, L-fucose appeared either to bind to the 
lymphokine or to otherwise affect the lymphokine-macrophage interaction but 
not to bind to macrophages, because macrophages pretreated with L-fucose and 
then washed retained the ability to respond to the lymphokine and phagocytize 
EIgMC (data not shown). 
Of several other pentoses and hexoses tested, including the stereoisomer of L- 
fucose, D-fucose,  none was able to abrogate the lymphokine's effect on macro- 
phages (Table  II).  In addition, only L-fucose prevented lympbokine-mediated 
complement receptor mobility (Table III). The most likely mechanism by which 
L-fucose interfered with the lymphokine's action on macrophages is by competi- GRIFFIN  AND  MULLINAX 
TABLE  II 
Effects of Sugars on the Ability of Lymphokine  to Activate Macrophage 
C3 Receptors for Phagocytosis 
Phagocytic Index of 
Sugar added at 0.1  M  to lymphokine  EIgMC 
None  201  +  50 
L-Fucose  37 _  12 
D-Fucose  190 +  56 
Mannose  227 _+ 47 
IZ~Galactase  189 +47 
N-Acetyl-D-glucosamine  239 ±  46 
Glucose  211  ±  59 
2-Deoxy-o-glucose  156 "4- 15 
Arabinose  141  +  11 
Xylose  154 _  10 
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TABLE  III 
Effects of Sugars on Lymphokine-induced  Macrophage  C3 Receptor 
Mobility 
Attachment Index of 
Sugar added at O. 1 M  to lymphokine  EIgMC 
None  55 -  8 
L-Fucose  955 ----. 22 
D-Fucose  51  4- 1 
Mannose  157 ±  120 
D-Galactase  39 ±  11 
N-Acetyl-D-glucosamine  42 +  15 
Glucose  64 ___ 8 
2-Deoxy-~glucose  128 +  49 
Arabinose  69 -t- 24 
Xylose  63 +  17 
tively binding the lymphokine and preventing its binding to L-fucose residues on 
the macrophage surface. 
Effect of Abolishing and  Masking  Macrophage Surface Fucose Residues on  the 
Macrophage's Ability to  Respond  to  the  Lymphokine.  We  explored  further  the 
requirement for cell surface fucose in two additional ways, by removing fucose 
residues  with  the  enzyme fucosidase and  by  masking  fucose residues  with  a 
fucose-specific lectin, gorse lectin. 
In  the  first  experiments,  macrophages were  treated  with  0.0017  U/ml  of 
fucosidase for 1 h at 37 o  C. Cells were washed to remove the enzyme and overlaid 
with lymphokine, and their ability to phagocytize EIgMC was determined. These 
cells  were  unable  to  phagocytize EIgMC  (Fig.  4).  Within  a  few  hours  after 
removal of the enzyme, they were fully able to respond to the lymphokine (Fig. 
4), indicating that fucosidase did not exert its effect by being cytotoxic. Control 
experiments revealed that fucosidase treatment had no effect on macrophages' 
ability to bind EIgMC or on the ability of thioglycollate-elicited macrophages to 
phagocytize EIgMC (data not shown). Parallel experiments revealed that the C3 1212  MACROPHAGE RECEPTOR  FOR  A  LYMPHOKINE 
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FZC;URE 4.  Effect of fucosidase treatment on macrophages' ability to respond to the lympho- 
kine. Macrophages were treated with 0.0017 U/ml of fucosidase for 30 rain at 37°C, washed, 
and assayed for their ability to ingest ElgMC immediately and at varying times after removal 
of fucosidase (+).  The ability of macrophages that were not treated  with fucosidase to 
ingest EIgMC was also assessed (,). 
TABLE  IV 
Effect of Fucosidase Treatment of Macrophages on Lymphokine- 
induced C3 Receptor Mobility 
Treatment of macrophages with:  Attachment Index of 
Fucosidase  Lymphokine  EIgMC 
-  -  1,047 _+ 138 
+  -  1,036 + 185 
-  +  53_+5 
+  +  1,002 _+ 184 
receptors of fucosidase-pretreated macrophages remained immobile even after 
lymphokine treatment (Table IV, line 4). 
In other experiments, macrophages were treated with 5 ~g/ml of a  lectin for 
30 min at 37°C.  Non-bound lectin was removed by washing, cells were overlaid 
with lymphokine, and their ability to ingest EIgMC was assessed.  Macrophages 
that  had  been  pretreated  with  gorse lectin,  which binds  specifically to  fucose 
(21),  were unable to ingest  EIgMC  (Table V,  line 2).  Gorse lectin did not act 
simply by perturbing the macrophage surface or by cross-linking or aggregating 
cell surface components because treatment of macrophages with any of five other 
lectins,  none  of which  binds  fucose,  was  without  effect  (Table  V).  Control 
experiments revealed that gorse lectin treatment had no effect on the ability of 
macrophages  to bind  EIgMC  or on the ability of thioglycollate-elicited macro- 
phages to ingest EIgMC (data not shown). 
In  parallel  experiments,  treatment  of macrophages  with  gorse lectin,  which 
prevented iymphokine activation of the cells' C3 receptors for phagocytosis, also 
prevented  the  lymphokine  from  mobilizing  the  macrophages'  C3  receptors 
(Table VI, line 2). Contrariwise, treatment of macrophages with iectins that did 
not alter one effect of the lymphokine on macrophages failed to alter the other 
lymphokine  effect  (Table  VI),  except  in  the  case  of Con  A.  Con  A-treated GRIFFIN  AND  MULLINAX 
TABLE V 
Effect of Lectin Treatment on Macrophages' Ability to Respond to the 
Lymphokine 
Lectin treatment  Sugar specificity of lectin  Phagocytic Index 
None  205 ±  29 
Gorse  Fucose  16 ±  12 
Lentil  Mannose/Glucose  172 ±  8 
Wheat germ  N-acetyl-~glucosamine  164 ±  21 
Pokeweed  ?  208 ±  52 
PHA  ?  291  ±  101 
Con A  Mannose  197 +  40 
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TABLE VI 
Effect of Lectin Treatment of Macrophages on Lymphokine-induced 
C3 Receptor Mobility 
Lectin treatment 
Attachment Index of EIgMC by macrophages 
Nontreated  Lymphokine-treated 
None  1,041  ±  130  65 __. 10 
Gorse  950 ±  80  869 ±  96 
Lentil  1,183 ±  64  89 __.14 
Wheat germ  1,166 ±  87  99 ±  4 
Pokeweed  1,078 ±  89  69 +16 
PHA  1,061  ±  103  83 ±  29 
ConA  817±56  698± 128 
macrophages retained the ability to respond to the lymphokine and phagocytize 
EIgMC; however, these macrophages also retained the ability to bind EIgMC 
even when plated on  complement-containing immune complexes and  treated 
with  lymphokine (Table  VI,  line  7),  suggesting that  their  C3  receptors were 
immobile yet able to promote phagocytosis. If so, our hypothesis that only mobile 
receptors  are  capable  of promoting  phagocytosis  would  be  open  to  serious 
question. 
We considered the possibility that the C3 receptors of macrophages plated on 
C3-containing immobilized immune complexes and treated first with Con A and 
then with lymphokine may have been mobile and may have become sequestered 
on the adherent macrophage surface but that these macrophages retained the 
ability to  bind  EIgMC  not via their C3  receptors but rather by macrophage- 
bound Con A. This possibility seemed plausible because we have previously used 
Con A to link E to macrophages (2).  If this were the mechanism by which Con 
A-pretreated, lymphokine-treated macrophages bound EIgMC, then these mac- 
rophages should be able to bind E and EIgM as well as EIgMC, and inclusion of 
mannose in the incubation mixture containing macrophages and EIgMC should 
markedly reduce EIgMC binding. As shown in Table VII, these are precisely the 
results we obtained.  Thus,  binding of EIgMC by these cells was mediated by 
macrophage-bound  Con  A.  The  cells'  C3  receptors  were  mobile  and  were 
sequestered on the adherent macrophage surface. Therefore, none of the control 1214  MACROPHAGE  RECEPTOR  FOR  A  LYMPHOKINE 
TABLE  VII 
Effect of Con A Treatment on Macrophages' Interaction with Sheep 
Erythrocytes 
Addition to  Particle offered  Attachment Index by Con 
incubation mixture  A-treated macrophages 
--  EIgMC  571 +  74 
--  E*  151  +  19 
--  EIgM*  214 _+ 18 
Mannose  EIgMC  123 +  37 
* Attachment indices for E and EIgM by macrophages that had not been 
treated with Con A were 7 and 6, respectively. 
lectins influenced either lymphokine activation of C3 receptor-mediated phago- 
cytosis or lymphokine-induced C3 receptor mobility. 
Results of these experiments, using fucosidase and using gorse lectin and other 
lectins, indicate that macrophage surface fucose is essential for macrophages to 
respond to the lymphokine that activates their C3 receptors for phagocytosis. It 
is most likely that fucose constitutes a  portion of the lymphokine-binding site, 
probably in a glycoprotein lymphokine receptor. 
Discussion 
Many  molecules that  elicit  responses  from  cells  act  by  binding  to  specific 
receptors on the cell's plasma membrane. Ligation of a receptor by the ligand 
modifies the receptor in  such a  way that it acquires new properties, often the 
ability to interact with second messenger molecules, which can then interact with 
other intracellular molecules (22). In this way ligand binding initiates signals that 
are transduced into activation or suppression of Cellular processes located at sites 
distant from the iigand and the receptor (22). 
In  the  present  studies  we  tested  the  hypothesis  that  the  lymphokine  that 
activates  macrophage C3  receptors  for  phagocytosis exerts  its  effect by  first 
binding to a receptor on the macrophage surface. The results obtained indicate 
that  the  lymphokine  must  bind  to  a  fucose-containing glycoprotein  on  the 
macrophage surface, perhaps a  specific receptor molecule. The protein nature 
of the molecule was deduced by the inability of Dispase-treated macrophages to 
respond to  the lymphokine, whereas the requirement for fucose was demon- 
strated  by  competitive  inhibition,  by  cleaving  fucose  from  the  macrophage 
surface, and by masking cell surface fucose with a lectin. 
Human (23) and guinea pig migration inhibitory factor (MIF) (24) and human 
lymphocyte-derived chemotactic factor (LDCF) (25) appear to bind to a fucose- 
bearing macrophage surface structure, as evidenced by competitive inhibition 
studies and  by treatment of cells with  fucosidase.  No data were presented in 
those studies to indicate whether or not the lymphokine-binding molecule was a 
protein. The similarity of binding requirements for different lymphokines raises 
several possibilities regarding the structure of the lymphokines and the nature 
of the lymphokine receptor(s). 
MIF,  LDCF,  and  the  lymphokine  that  activates  macrophage  complement 
receptors might be the same molecule. However, because the latter lymphokine GRIFFIN AND  MULLINAX  1215 
is  not  generated  by  mechanisms that  generate  the  first  two  (1),  because  its 
apparent molecular weight (~10,000) is lower than that of MIF (2), and because 
lymphokines from three species as divergent as man, mouse, and guinea pig are 
unlikely to be identical molecules, this possibility seems remote. However, it is 
possible that one of the lymphokines might be derived, e.g., by cleavage, from 
another or that the lymphokines have similar or identical binding sites.  If the 
second possibility is correct, then the lymphokines may be a family of molecules 
derived originally by gene duplication and preserved over a  long evolutionary 
period. 
There is very little information concerning the nature of putative lymphokine 
receptor sites. The present studies suggest that the site to which the lymphokine 
that activates  macrophage C3  receptors binds  is a  glycoprotein, and  this and 
other studies (23-25) demonstrate the critical role of fucose residues in mediating 
binding of a number of iymphokines. These results suggest that either a single 
receptor may recognize a  number of different lymphokines or that  different 
lymphokine  receptors  bear  structural  similarities,  especially  in  their  ligand- 
binding sites. These distinctions can be made only as the receptors are purified 
and studied at  the molecular level.  Gorse lectin, which binds the lymphokine 
that  activates  macrophage  C3  receptors and  presumably  would  bind  to  the 
receptor(s) for MIF and LDCF as well, might prove very useful in purification 
of lymphokine receptors from macrophage plasma membranes. 
Triggering receptors with lectins often induces a cellular response that mimics 
the response  induced by the natural ligand.  Examples include mitogenesis of 
lymphocytes induced by Con A or PHA (26) and the induction of chemotaxis of 
human neutrophils by the fucose-binding Lotus tetragonolobus  lectin (27). In the 
present studies, gorse lectin presumably bound to the lymphokine receptor and 
prevented lymphokine binding but did not itself induce the lymphokine effect. 
Thus, the lectin acted as a competitive antagonist, indicating that the manner in 
which  a  lymphokine  receptor  is  ligated,  rather  than  simply  ligation  per  se, 
determines whether or not the bound ligand will activate the receptor to produce 
a biologic response. 
We have previously presented evidence that the lymphokine activates macro- 
phage C3 receptors for phagocytosis by freeing anchored receptors and allowing 
them to diffuse within the cell's plasma membrane (5, 6). In the present experi- 
ments,  whenever a  treatment  of macrophages  or  of lymphokine  prevented 
lymphokine activation of macrophage C3 receptors for phagocytosis, that treat- 
ment also prevented lymphokine-induced C3  receptor mobility. These results 
strengthen our hypothesis that, for a receptor to be able to promote phagocytosis, 
it must be able to diffuse within the macrophage plasma membrane. 
In conjunction with previous studies of the lymphokine that activates macro- 
phage C3 receptors (1-6), the present studies represent an example in which one 
receptor affects the function of another receptor by inducing a qualitative change 
in  receptor behavior.  Other ligand-receptor interactions have been shown to 
induce qualitative changes in C3 receptor behavior in other cells. For example, 
binding of fibronectin to fibronectin receptors or of phorbol myristate acetate 
(PMA) to PMA receptors of human monocytes activated the cells' C3b receptors 
and C3bi  receptors for phagocytosis (28-30).  In other studies, ligating human 1216  MACROPHAGE  RECEPTOR  FOR  A  LYMPHOKINE 
monocytes' C3b receptors induced changes not only in the distribution of C3b 
receptors but also in the topography of the cells' Fc receptors, and, conversely, 
ligating Fc receptors altered the topography of both Fc and C3b receptors (31). 
Similarly, ligating chemotactic factor receptors of neutrophils caused previously 
randomly distributed Fc receptors to accumulate at the cell's leading edge (32). 
Finally,  iigating the human neutrophii C3bi  receptor, or a  closely associated 
plasma membrane structure, with antibody abrogated the ability of the cell's Fc 
receptors and C3b receptors to promote phagocytosis, without affecting their 
ability to  bind ligand-coated particles (33),  strongly suggesting that  the C3bi 
receptor normally regulates the function of both C3b and Fc receptors. Further 
evidence in support of that hypothesis is the finding that neutrophils which, as a 
consequence of a  genetic defect, lack the C3bi receptor, or a  closely related 
protein, are  unable to phagocytize via either their C3b receptors or their  Fc 
receptors (34).  Further studies of the interactions between these immunologic 
receptors  may  provide  valuable  insights  into  general  mechanisms by  which 
receptors  communicate  with  one  another  and  by  which  receptors  regulate 
functions not only of intracellular molecules but also of cell surface structures. 
Summary 
Macrophage  receptors  for  the  third  component of  complement (C3)  are 
normally immobilized and unable to diffuse within the cell's plasma membrane 
and, even though they promote avid particle binding, are unable to promote 
phagocytosis of C3-coated particles. We have previously identified a lymphokine 
that activates macrophage C3 receptors for phagocytosis and have found that it 
acts by freeing the receptors so that they can diffuse within the macrophage 
plasma membrane. 
It seemed likely to us that the initial lymphokine-macrophage  interaction would 
occur at the macrophage surface, perhaps via a  specific lymphokine receptor. 
Since the binding of many ligands to cells is mediated by cell surface glycopro- 
teins, we examined the protein and sugar requirements for murine peritoneal 
macrophages  to  respond  to  the  lymphokine.  Macrophages  treated  with  the 
neutral  protease  Dispase  lost  the ability  to  respond to  the  lymphokine, and 
inclusion  of L-fucose in  the  incubation  medium containing lymphokine and 
macrophages inhibited markedly the macrophages' response to the lymphokine, 
suggesting that the lymphokine  exerts its effects by first binding to fucose residues 
on a glycoprotein receptor on the macrophage surface. Further evidence for the 
essential role of macrophage surface fucose was obtained by demonstrating that 
pretreatment of macrophages with either fucosidase or gorse lectin, a  fucose- 
binding iectin, strikingly disabled the cells from responding to the lymphokine. 
All treatments that prevented lymphokine  activation of macrophage C3 receptors 
for phagocytosis also prevented lymphokine-induced C3 receptor mobility. 
These results strongly suggest that the lymphokine binds to a fucose-bearing 
macrophage surface glycoprotein, perhaps a specific lymphokine receptor. They 
also  strengthen  our  hypothesis  that,  for  a  receptor  to  be  able  to  promote 
phagocytosis, it must be able to diffuse within the macrophage plasma membrane. 
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